Semaglutide: The Drug that May Lead to a 'New Era' in Anti-Obesity Medication

Historically, most weight-loss drugs can only reduce weight by 5-10%, and there are many hidden safety risks. In clinical trials, smeglutide not only reduced the weight of obese patients by an average of 15%, but also showed good safety.

As scientists have a deeper understanding of the molecular mechanism of signal communication between the intestine and the brain, a variety of new generations of weight loss therapies are emerging. Recently, a review of Nature Reviews Drug Discovery, a sub-published by Nature, counted these innovative therapies.

Both Tirzepatide and smeglutide reduced the weight of obese patients by more than 10% in phase 3 clinical trials, breaking the historical limitation that weight loss drugs can only reduce weight by 5% to 10%. The review authors stated that they set a new benchmark for the development of a new generation of weight-loss drugs.